(Albany, US), November 04, 2026 – DelveInsight’s ‘Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Market Insights, Epidemiology and Market Forecast – 2036’ report delivers an in-depth understanding of Gastroenteropancreatic Neuroendocrine Tumors, historical and forecasted epidemiology, as well as the Gastroenteropancreatic Neuroendocrine Tumors market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Explore the intricate details of the Gastroenteropancreatic Neuroendocrine Tumors Market Report @ Gastroenteropancreatic Neuroendocrine Tumors Market Size
Key Takeaways from the Gastroenteropancreatic Neuroendocrine Tumors Market Report
According to Camurus AB’s 2026 presentation, results from the Phase III SORENTO trial are anticipated to be presented in 2026.
The GEP-NET market is anticipated to grow at a significant CAGR during the forecast period of 2026-2036.
According to DelveInsight’s analysis, the US contributed the highest number of incident cases of NETs, with total incident cases of NETs in the United States in 2025 being 31,000.
GEP-NETs represent the most common NET subtype, comprising 50–70% of all NETs.
A significant proportion of GEP NET express somatostatin receptors, particularly in well and moderately differentiated tumors, which underpins the use of somatostatin analogs and peptide receptor radionuclide therapies.
Despite advances in diagnostics, GEP-NET are often not identified for up to 5–7 years after clinical symptoms appear, as the symptoms are not specific.
Radiomedix and Orano Med are developing AlphaMedix, the first radioligand therapy to receive BTD, which has demonstrated a response rate of 62.5% in GEP-NET patients who had not previously undergone PRRT with LUTATHERA.
The development of innovative therapies, particularly radioligand treatments and alpha emitter-based therapies, is driving growth in the Gastroenteropancreatic Neuroendocrine Tumors market, while manufacturing and administration challenges and generic competition remain barriers.
The leading GEP-NET companies include Novartis, Pfizer, Exelixis, Ipsen Biopharmaceuticals, ITM Isotope Technologies Munich, Camurus AB, Bristol Myers Squibb, RayzeBio, and others.
Promising GEP-NET therapies include LUTATHERA (lutetium Lu 177 DOTATATE), SOMATULINE DEPOT (Lanreotide), ZANOSAR (Streptozocin), ITM-11 (n.c.a. 177Lu-edotreotide), CAM2029, RYZ101, and others.
Get a Free sample for the Gastroenteropancreatic Neuroendocrine Tumors Market Forecast, Size & Share Analysis Report @ GEP-NET Market Forecast
Gastroenteropancreatic Neuroendocrine Tumors Overview
Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) are rare, heterogeneous cancers arising from neuroendocrine cells in the gastrointestinal tract and pancreas. Their complexity and late-stage presentation require individualized treatment based on tumor grade, location, hormone activity, and patient symptoms, with management primarily focused on advanced and metastatic disease. Incidence has increased over recent decades, partly due to enhanced detection and imaging practices, although exact rates vary by region and subtype. Diagnosis of GEP NET relies on a combination of biochemical testing, imaging, and sometimes genetic evaluation. Common biochemical markers include chromogranin A, pancreatic hormones (insulin, gastrin, glucagon), and serotonin metabolites such as 5-HIAA in urine, depending on tumor functionality. Imaging studies such as contrast-enhanced CT and MRI are used to localize primary tumors and assess metastatic spread.
Gastroenteropancreatic Neuroendocrine Tumors Epidemiology Segmentation in the 7MM
Total Incident Cases of NET
Total Incident Cases of GEP-NET
Grade-specific Incident Cases of GEP-NET
Functional status Incident Cases of GEP-NET
Stage-specific Incident Cases of GEP-NET
SSR Positive Incident Cases of GEP-NET
Total Treated Cases of GEP-NET
Download the report to understand which factors are driving Gastroenteropancreatic Neuroendocrine Tumors Epidemiology trends @ GEP-NET Epidemiology
Gastroenteropancreatic Neuroendocrine Tumors Epidemiology Key Findings
The US contributed to the highest incident cases of NETs. The total incident cases of NETs in the United States in 2025 were 31,000.
According to secondary research, the incidence of malignant GEP-NET during 2000–2007 was 1.7 per 100,000 population per year in Europe, corresponding to an estimated 26,000 new cases.
In Spain, the annual incidence of the disease was 6.47 cases per 100,000 population, with an adjusted prevalence of 0.052%. The mean age at diagnosis was 58 ± 15 years, and the gender distribution was nearly equal, with 51% men and 49% women.
Surgical resection of the primary tumor was performed in 66% of patients. Histopathological grading showed that most tumors were well differentiated, with 73% classified as Grade 1 (G1), 22% as Grade 2 (G2), and 5% as Grade 3 (G3).
The most common primary tumor site was the pancreas (52%), followed by the jejunum–ileum (23%). At the time of diagnosis, 24% of patients presented with distant metastases, most frequently involving the liver (44%), peritoneum (25%), or multiple organs (22%). The majority of tumors were sporadic and non-functional.
Approved Therapies for Gastroenteropancreatic Neuroendocrine Tumors
LUTATHERA (lutetium Lu 177 DOTATATE): Novartis
LUTATHERA is indicated for adult patients with somatostatin receptor-positive GEP-NET. In September 2017, the EMA approved LUTATHERA for the treatment of GEP-NET, the first time a radioactive drug, or radiopharmaceutical, has been approved for the treatment of GEP-NET. LUTATHERA has demonstrated meaningful progression-free survival benefits, and it is also approved for supply in Australia, listed on the Australian Register of Therapeutic Goods (ARTG) under ARTG number 455452, with a registration date of November 2025.
SOMATULINE DEPOT (lanreotide): Ipsen Biopharmaceuticals
SOMATULINE DEPOT is a SSA indicated for the treatment of adult patients with unresectable well or moderately differentiated, locally advanced, or metastatic GEP-NET to improve progression-free survival. The drug is also approved for the treatment of adults with carcinoid syndrome by reducing the frequency of short-acting SSA rescue therapy. It is administered subcutaneously.
ZANOSAR (Streptozocin): Pfizer
ZANOSAR is a small molecule alkylating anti-tumor antibiotic administered by IV infusion, approved for PNET/GEP-NET (US: 1982 for PNET; JP: 2014 for GEP-NET).
Discover more about therapies set to grab Major Gastroenteropancreatic Neuroendocrine Tumors Market Share @ GEP-NET Market Drivers and Barriers
Gastroenteropancreatic Neuroendocrine Tumors Pipeline Analysis
ITM-11 (n.c.a. 177Lu-edotreotide): ITM Isotope Technologies Munich
ITM-11 is an innovative targeted radionuclide therapy agent being developed by ITM Isotope Technologies Munich. It is currently being investigated in two Phase III clinical trials, COMPETE (GEP-NET G1/G2) and COMPOSE (well-differentiated high Grade 2 and Grade 3 GEP-NET). In November 2025, ITM announced that the FDA completed its filing review and accepted the company’s New Drug Application for 177Lu-edotreotide, with a PDUFA goal date of August 28, 2026.
CAM2029: Camurus AB
CAM2029 is a ready-to-use, long-acting, subcutaneous depot of octreotide being developed by Camurus AB. Studies completed to date demonstrate that CAM2029 has the potential to provide significantly higher octreotide bioavailability and exposure compared to current market-leading products, and it is designed to enable easy self-administration, including the option of a pre-filled pen device. The drug is being evaluated in the Phase III SORENTO study in patients with GEP-NET, with PFS readout data anticipated in mid to late 2026.
RYZ101: RayzeBio
RYZ101 is an emerging radioligand therapy designed to deliver targeted alpha radiation to somatostatin receptor–expressing tumors, currently in Phase III for SSTR+ GEP-NET.
Gastroenteropancreatic Neuroendocrine Tumors Market Outlook
The Gastroenteropancreatic Neuroendocrine Tumors market is undergoing a steady shift as deeper insights into tumor biology and receptor expression patterns reshape treatment approaches. GEP NET management is now benefiting from advances in targeted pathways, including mTOR inhibition and somatostatin receptor directed strategies, which are improving disease stabilization and delaying progression, particularly in patients with well-differentiated tumors. At the same time, radioligand-based therapies continue to evolve, with ongoing refinements in peptide receptor targeting and radionuclide design, as seen with agents such as LUTATHERA and Iodine-131 metaiodobenzylguanidine (131I-MIBG). The clinical pipeline is expanding with novel agents, including next-generation receptor-targeted compounds, angiogenesis inhibitors such as sunitinib, and combination regimens designed to address resistance and tumor heterogeneity. Improvements in functional imaging, including Ga-68 DOTATATE PET/CT, and biomarker research are also enabling more accurate disease monitoring and treatment selection. Overall, growing clinical interest, increasing diagnosis rates, and continued innovation in targeted and radioligand therapies are expected to support sustained growth across major regions, while emerging candidates such as surufatinib and 177Lu-edotreotide are anticipated to increase competition.
Gastroenteropancreatic Neuroendocrine Tumors Market Drivers
Increasing incidence and improved diagnosis
Advancements in targeted and radioligand therapies
Expanding research and clinical pipeline
Rising awareness and early detection programs
Favorable regulatory support for rare cancers, including orphan drug incentives, accelerated approvals, and supportive reimbursement policies
Gastroenteropancreatic Neuroendocrine Tumors Market Barriers
Complex nature of GEP-NET
Challenges in drug manufacturing and administration
Impact of generic competition on the sales of approved drugs
Diagnostic delays, as symptoms are not specific
Gastroenteropancreatic Neuroendocrine Tumors Treatment Landscape
Surgery, the only curative treatment for GEP-NET, is generally considered a first-line treatment for localized NETs. For advanced, metastatic, or unresectable disease, treatment options include peptide receptor radionuclide therapy (PRRT) with LUTATHERA, somatostatin analogs such as octreotide and lanreotide to control hormone-related symptoms and tumor growth, targeted therapies like everolimus and sunitinib for pancreatic NETs, and cytotoxic chemotherapy (temozolomide or capecitabine-based regimens) for high-grade tumors. Key unmet needs include diagnostic delays and disease presentation, treatment resistance and disease progression, resistance to standard therapies, and gaps in long-term disease management.
To know more about GEP-NET Companies working in the treatment market, visit @ Will Insurance Cover PRRT for GEP-NET?
Scope of the Gastroenteropancreatic Neuroendocrine Tumors Market Report
Coverage- 7MM
Study Period- 2022-2036
Forecast Period- 2026-2036
Gastroenteropancreatic Neuroendocrine Tumors Companies- Novartis, Pfizer, Exelixis, Ipsen Biopharmaceuticals, ITM Isotope Technologies Munich, Camurus AB, Bristol Myers Squibb, RayzeBio, and others.
Gastroenteropancreatic Neuroendocrine Tumors Therapies- LUTATHERA (lutetium Lu 177 DOTATATE), SOMATULINE DEPOT (Lanreotide), ZANOSAR (Streptozocin), ITM-11 (n.c.a. 177Lu-edotreotide), CAM2029, RYZ101, and others.
Gastroenteropancreatic Neuroendocrine Tumors Market Dynamics: Gastroenteropancreatic Neuroendocrine Tumors market drivers and market barriers
Gastroenteropancreatic Neuroendocrine Tumors Competitive Intelligence Analysis: SWOT Analysis, Conjoint Analysis
Gastroenteropancreatic Neuroendocrine Tumors Unmet Needs, KOL Views, Reimbursement
Table of Contents
Key Insights
Report Introduction
Executive Summary
Key Events
Epidemiology and Market Methodology of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)
Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Market Overview at a Glance
Disease Background and Overview of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)
Epidemiology and Patient Population of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)
Patient Journey of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)
Marketed Therapies
Emerging Therapies
Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET): Seven Major Market Analysis
Unmet Needs of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)
SWOT Analysis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)
KOL Views of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)
Market Access and Reimbursement of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)
Appendix
DelveInsight Capabilities
Disclaimer
About DelveInsight
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Abhishek kumarEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-market
